Advances of next-generation immune checkpoint blockade / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 238-240, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-693485
ABSTRACT
Immune checkpoint blockades can induce long lasting responses but only in a fraction of patients owing to deficient of antibody as well as the neglect of immune suppressive cells.Next-generation immune checkpoint blockades,including FcγR-binding anti-programmed cell death-1 (PD-1)/PD ligand 1 (PD-L1) antibodies,co-inhibitors of immune checkpoint,small-molecule modulators and antibody-drugs conjugated with PD-1/PD-L1,will overcome the deficiencies of current anti-PD-1/PD-L1 antibodies and will become the direction of immunotherapy in the future.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS